Company / Current Liabilities per Share
CRISPR Therapeutics AG Current Liabilities per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$1.56
FY2025
5-year range
$1.02 / $1.56
FY2021-FY2025
Trend
+51.9%
vs FY2024
Sector context
#80 of 210
Health Care
What the data says
At $1.56, CRISPR Therapeutics AG's current liabilities per share ranks #131 of 210 in the Health Care sector. Current Liabilities per Share returned to growth in FY2025 after 3 years of decline, reaching $1.56.
Based on SEC 10-K filings.
1.56 in FY2025 with a 5-year CAGR of +4.0%.
Increased from $1.36 to $1.56 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- +0.3%
- 5-Year CAGR
- +4.0%
- 10-Year CAGR
- -
Sector benchmark
#131 of 210 in Health CareTop 62% of 210This company $1.56 Sector average $23.75
▼
-93.5% below sector average
Key checks
Key Insights
- In FY2025, current liabilities per share increased 51.9% year-over-year.
- Ranks #80 out of 210 companies in the Health Care sector.
- Peak current liabilities per share was recorded in FY2016.
- Lowest current liabilities per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.56 | +51.9% |
| FY2024 | $1.02 | -24.7% |
| FY2023 | $1.36 | -11.9% |
| FY2022 | $1.54 | -0.9% |
| FY2021 | $1.56 | +22.1% |
| FY2020 | $1.28 | +15.8% |
| FY2019 | $1.10 | +61.1% |
| FY2018 | $0.68 | +87.1% |
| FY2017 | $0.37 | -90.8% |
| FY2016 | $3.98 | +97.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026